You are here

FDA Sets Review Date for New COPD Drug, Anoro Ellipta

Approval decision expected in December (Feb. 19)

The FDA has accepted the new drug application (NDA) for an investigational once-daily LAMA/LABA combination medicine — umeclidinium bromide and vilanterol (UMEC/VI, GlaxoSmithKline/Theravance) — for patients with chronic obstructive pulmonary disease (COPD).

The Prescription Drug User Fee Act (PDUFA) goal date is December 18, 2013.

UMEC/VI — with the proposed brand name of Anoro — is a combination of two investigational bronchodilator molecules: umeclidinium bromide (formerly known as GSK573719, a long-acting muscarinic antagonist [LAMA]) and vilanterol (a long-acting beta2 agonist [LABA]). The combo drug is administered using the Ellipta inhaler.

Source: GSK; February 19, 2013.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels